Boston Scientific (BSX) Stock Forecast & Price Target

$83.80

+0.45 (+0.54%)

(As of 09/30/2024 ET)

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
2

Buy
18

Based on 20 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 2 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$86.65
3.40% Upside

According to the 20 analysts' twelve-month price targets for Boston Scientific, the average price target is $86.65. The highest price target for BSX is $95.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 3.40% from the current price of $83.80.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

BSX Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	17 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	15 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.65	$85.24	$77.41	$60.10
Forecasted Upside	3.40% Upside	4.22% Upside	1.71% Upside	13.80% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Protect Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.95	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	3.40% Upside	823.07% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent BSX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Raymond James 4 of 5 stars	Boost Target	Strong-Buy ➝ Strong-Buy	$91.00 ➝ $94.00	+15.85%
8/22/2024	Citigroup 3 of 5 stars	Boost Target	Buy ➝ Buy	$90.00 ➝ $92.00	+15.77%
8/22/2024	Barclays 3 of 5 stars	Boost Target	Overweight ➝ Overweight	$78.00 ➝ $86.00	+8.08%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$73.00 ➝ $78.00	+2.63%
7/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$85.00 ➝ $85.00	+12.02%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$82.00 ➝ $85.00	+8.83%
Get the Latest News and Ratings for BSX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.
7/25/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$83.00 ➝ $88.00	+13.17%
7/25/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$82.00 ➝ $86.00	+10.60%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$90.00 ➝ $91.00	+17.03%
7/16/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$77.00 ➝ $86.00	+10.16%
7/16/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$86.00 ➝ $90.00	+15.55%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$79.00 ➝ $92.00	+17.86%
7/15/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$80.00 ➝ $84.00	+7.61%
7/2/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$78.00 ➝ $81.00	+6.49%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$90.00	+20.05%
5/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+26.51%
5/15/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $90.00	+22.50%
4/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$74.00 ➝ $90.00	+22.97%
4/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$72.00 ➝ $82.00	+11.58%
2/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $68.00	+5.44%
9/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$58.00 ➝ $60.00	+10.91%
7/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$58.00 ➝ $62.00	+16.43%
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Initiates
6/30/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00	+20.10%
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00	+26.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:21 AM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 23, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Boston Scientific Co. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
The company's recent quarterly earnings report exceeded analysts' expectations, showcasing a positive trend in profitability.
With a diverse portfolio of medical devices for various specialties, Boston Scientific Co. has a wide market reach and potential for continued innovation.
Positive analyst ratings and an average target price above the current stock price suggest a favorable outlook for the company's stock.
Boston Scientific Co.'s stock has been trading near its 52-week high, reflecting investor confidence and potential for further growth.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

Despite positive analyst ratings, the stock may be considered overvalued based on its current price compared to the average target price.
The company's high price-to-earnings ratio of 70.01 indicates that the stock may be trading at a premium relative to its earnings.
Boston Scientific Co. operates in a competitive industry with rapid technological advancements, posing risks of market saturation and product obsolescence.
Recent insider selling activity, including significant sales by executives, could raise concerns about internal confidence in the company's future performance.
Market volatility and economic uncertainties may impact the medical device sector, affecting Boston Scientific Co.'s stock price and growth prospects.

BSX Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $86.65, with a high forecast of $95.00 and a low forecast of $68.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BSX shares.
: According to analysts, Boston Scientific's stock has a predicted upside of 3.40% based on their 12-month stock forecasts.
: Boston Scientific has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, TD Cowen, and Truist Financial in the past 90 days.
: Analysts like Boston Scientific more than other "medical" companies. The consensus rating score for Boston Scientific is 2.95 while the average consensus rating score for "medical" companies is 2.78. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Shedding light on a dark secret (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

This page (NYSE:BSX) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners